Table 4.

Studies of PPI and amoxicillin dual therapies as first-line Helicobacter pylori treatment

Studies	Study design	Sample size	Dose of PPI	Dose of amoxicillin	Treatment duration (days)	Eradication rates (ITT)
Koizumi W et al 32	RCT	31	Omeprazole 20 mg qd	500 mg tid	14	42%
Cottrill MR et al 33	RCT	85	Omeprazole 40 mg qd	1000 mg twice daily	14	44%
Wong BC et al 34	RCT	75	Lansoprazole 30 mg twice daily	1000 mg twice daily	14	57%
Schwartz H et al 35	RCT	60	Lansoprazole 30 mg twice daily	1000 mg tid	14	45%
Schwartz H et al 35	RCT	60	Lansoprazole 30 mg tid	1000 mg tid	14	70%
Yang J et al 36	RCT	116	Esomeprazole 20 mg qid	750 mg qid	14	88%
Yu L et al 37	RCT	80	Esomeprazole 40 mg twice daily	1000 mg tid	14	93%
Yang JC et al 38	RCT	150	Rabeprazole 20 mg qid	750 mg qid	14	95%
Furuta et al 39	Retrospective study	56	Vonoprazan 20 mg twice daily	500 mg tid	7	93%
Present study	RCT	168	Vonoprazan 20 mg twice daily	750 mg twice daily	7	85%

ITT, intention-to-treat; PPI, proton-pump inhibitor; qd, once daily; qid, four times daily; RCT, randomised controlled trial; tid, three times daily.